Paul van der Horst

Chief Business Officer

Paul joined Agomab in 2021 as Chief Business Officer. Prior to Agomab, he was Head of Corporate Development at Galapagos from 2016-2021. In this role, he led all major transactions, investments, licensing and M&A activities for the company. Most notably, he was a key negotiator for Galapagos’ transformative $5bn strategic collaboration with Gilead Sciences. From 2013-2016, he worked at boutique investment bank Kempen & Co in Amsterdam, where he was responsible for broking and dealing of European pharma & biotech stocks to institutional investors in Europe and the US. In addition, Paul is a member of the Board of Directors at ImmuneTune (Leiden, The Netherlands). Paul studied medicine and holds a PhD in Gynaecological Oncology from the Erasmus University Medical Centre in Rotterdam, The Netherlands.

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.